MedPath

Safety and efficacy of sedation with midazolam during bronchoscopy

Not Applicable
Conditions
Respiratory disease, which is an indication of flexible bronchoscopy
Registration Number
JPRN-UMIN000023619
Lead Sponsor
Department of Respiratory Medicine Nagoya University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients with SpO2 <90% in the room air 2. There is a history of severe drug hypersensitivity, including hypersensitivity to midazolam 3. Patients with a neuromuscular disease 4. Patients with acute angle-closure glaucoma 5. Patients with myocardial infarction within-onset 6 weeks 6. Patients with other serious complications 7. Patients whom the attending physician has determined to be inappropriate as a subject of the present study

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Occurrence rate of hypoxemia during bronchoscopy
Secondary Outcome Measures
NameTimeMethod
1. Blood concentrations of midazolam (after the initial dose, after adding administration) 2. MOAA/S scale 3. The bispectral index (BIS) 4. Questionnaire about the sedation 5. Adverse events 6. Correlation between gene polymorphism and efficacy or safety of sedation
© Copyright 2025. All Rights Reserved by MedPath